Evecxia is the first company dedicated to realizing the therapeutic potential of amplifying serotonin synthesis to treat brain disorders. Serotonin synthesis amplification is distinct from targeting serotonin transporters (e.g., SSRIs) and receptors (e.g., psilocybin). Evecxia deploys 5-HTP, the natural serotonin precursor, delivered via proprietary drug delivery technologies to achieve sustained serotonin synthesis amplification. Evecxia has two Phase 2 clinical-stage drug candidates in development. EVX-101 is being developed as an adjunctive treatment for depression when first-line SSRI/SNRI antidepressants alone are inadequate. EVX-301 is being developed as a rescue therapy for patients in acute suicidal ideation crisis. Evecxia holds a comprehensive portfolio of issued and pending patents on the 5-HTP sustained-release/serotonin amplification method, doses, formulations, and related technologies.
| Website | http://www.evecxia.com |
| Revenue | $8 million |
| Employees | 6 (2 on RocketReach) |
| Founded | 2013 |
| Phone | +1 919-597-8762 |
| Industry | Biotechnology, Manufacturing General, Health Care, Manufacturing, Therapeutics |
| Keywords | Brain Health, Neurological Disorders, Mental Health, Neurological Treatment, Psychiatric Disorders, Neurological Research, Innovative Therapies, Central Nervous System, Novel Therapeutics, Therapeutic Innovation, Drug Development, Clinical Trials, Biotechnology, Psychedelic Medicine, Pharmaceutical |
| Competitors | Alkermes, Axovant Sciences Ltd, Intra-Cellular Therapies, Sage Therapeutics, Neuralstem, Inc., Ovid Therapeutics, Zynerba Pharmaceuticals, Catalyst Pharmaceuticals, Inc., Alder BioPharmaceuticals, Inc., Intellia Therapeutics, Inc. +33 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies |
Looking for a particular Evecxia Therapeutics, Inc. employee's phone or email?
Evecxia Therapeutics, Inc. Questions
The Evecxia Therapeutics, Inc. annual revenue was $8 million in 2026.
Jacob Jacobsen is the CEO of Evecxia Therapeutics, Inc..
2 people are employed at Evecxia Therapeutics, Inc..
The NAICS codes for Evecxia Therapeutics, Inc. are [32541, 32, 3254, 325].
The SIC codes for Evecxia Therapeutics, Inc. are [28, 283].
Top Evecxia Therapeutics, Inc. Employees
-
32
-
John Kaiser
Member Board Of Directors at Evecxia Therapeutics, Inc.
Westfield, IN, US45+
Related Companies
